Trial Profile
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety Circuits in Response to Food Stimuli in Obesity and Diabetes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Braini-Ex
- 24 Sep 2013 Status changed from recruiting to completed.
- 24 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 03 Oct 2011 Actual initiation date (Sep 2011) added as reported by ClinicalTrials.gov.